156 related articles for article (PubMed ID: 17984671)
1. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction.
Pires MJ; Rodríguez-Peña AB; Arévalo M; Cenador B; Evangelista S; Esteller A; Sánchez-Rodríguez A; Colaço A; López-Novoa JM
J Hypertens; 2007 Dec; 25(12):2486-96. PubMed ID: 17984671
[TBL] [Abstract][Full Text] [Related]
2. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
4. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
[TBL] [Abstract][Full Text] [Related]
5. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
Grassi G; Trevano FQ; Facchini A; Toutouzas T; Chanu B; Mancia G
Blood Press Suppl; 2003 Dec; 2():35-40. PubMed ID: 14761075
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Toblli JE; Cao G; Casas G; Mazza ON
Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
Mahmud A; Feely J
Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
[TBL] [Abstract][Full Text] [Related]
9. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
Greven J; Gabriëls G
Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
[TBL] [Abstract][Full Text] [Related]
10. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
11. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
12. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
13. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
14. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation.
Fratta Pasini A; Garbin U; Nava MC; Stranieri C; Davoli A; Sawamura T; Lo Cascio V; Cominacini L
J Hypertens; 2005 Mar; 23(3):589-96. PubMed ID: 15716701
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
Oelze M; Daiber A; Brandes RP; Hortmann M; Wenzel P; Hink U; Schulz E; Mollnau H; von Sandersleben A; Kleschyov AL; Mülsch A; Li H; Förstermann U; Münzel T
Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222
[TBL] [Abstract][Full Text] [Related]
16. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.
de Nigris F; Rienzo M; Schiano C; Fiorito C; Casamassimi A; Napoli C
Eur J Cancer; 2008 Feb; 44(3):334-40. PubMed ID: 18194856
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
Zanchetti A
Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
[TBL] [Abstract][Full Text] [Related]
18. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure.
de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
J Cardiovasc Pharmacol; 2007 Jul; 50(1):56-60. PubMed ID: 17666916
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
Kuroedov A; Cosentino F; Lüscher TF
Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
[TBL] [Abstract][Full Text] [Related]
20. Protective role of gamma-aminobutyric acid against chronic renal failure in rats.
Sasaki S; Yokozawa T; Cho EJ; Oowada S; Kim M
J Pharm Pharmacol; 2006 Nov; 58(11):1515-25. PubMed ID: 17132215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
